Is This Jazz Pharmaceuticals' Worst Nightmare?

Shares of orphan drugmaker Jazz Pharmaceuticals have more than doubled in the last year, propelled by growing sales of its narcolepsy drug Xyrem. But a hidden danger may derail this growth stock in the near future.

Jun 19, 2014 at 5:00PM

Like most sports leagues, the biopharma industry is rife with copy-cats. When a drug sells well, you can rest assured someone is trying to come up with a rival or formulate a generic. 

Jazz Pharmaceuticals (NASDAQ:JAZZ) is a Dublin-based orphan drug specialist whose shares have risen an eye-popping 115% in the past year. This stellar growth in is not without merit, however.

Jazz's growth as been propelled mainly by the double-digit growth of its top two commercial products Xyrem and Erwinaze. And despite a skyrocketing share price, short-sellers have largely left the company to its own devices, suggesting a fair amount of market optimism about the stock's share price.

JAZZ Chart

JAZZ data by YCharts.

What's essential to understand is that Jazz relies heavily upon Xyrem for top-line growth, as the drug presently accounts for 65.8% of total net product sales. Even so, there are two serious threats to Xyrem's growth prospects that are perhaps going unnoticed by the wider market. 

Generic competition may come much sooner than anticipated
Although Jazz holds a series of patents for Xyrem that don't expire until 2019 to 2024, that hasn't stopped generic drugmakers from trying. In 2010, Roxane submitted an ANDA to the Food and Drug Administration requesting approval to market a generic version of Xyrem. Roxane's argument is largely that Jazz's patents for Xyrem are invalid. Jazz subsequently filed a lawsuit against Roxane as an attempt to block the entry of a generic.

Fast-forward to today, the case is still unresolved, and two additional companies have filed ANDAs for generic versions of Xyrem. Sifting through this legal mess, what's important to understand is that a trial could be held as early as the fourth quarter of this year. Given that the FDA has refused Jazz's petition to deny further ANDAs from being reviewed by the agency, this case is an important issue to keep tabs on going forward. 

A serious rival formulation is showing promise in clinical trials
Generic rivals for a drug still under patent protection are one thing. But a rival with a better dosing regimen and similar clinical outcomes is another issue altogether.  

Little-known French biopharma Flamel Technologies (NASDAQ:FLML) has been busy developing an alternative treatment for nacrolepsy based on its Micropump technology. Presently, Xyrem is dosed in two stages: once before bedtime and again 2.5 to 4 hours later. What this means is that you may have to wake up to take the second dose, interrupting nighttime sleep.

The goal of Flamel's Micropump approach is to deliver a dose of sodium oxybate (Xyrem) in a manner that would allow it to be taken only once. Although the company is still in the early stages of developing this technology, Flamel believes it could push it into a registration study by 2015.

Since Micropump has already been validated in other drugs, and the primary goal will simply to be to deliver a more efficient dose of sodium oxybate, Jazz shareholders should definitely keep a keen eye on this device as it progresses in clinical studies. 

Foolish wrap-up
It's commonplace for generic drugmakers to challenge the patents of highly successful drugs like Xyrem. And most of the time, they fail to make headway in invalidating the drug's patents. I suspect Xyrem's patents will hold up to legal scrutiny, which is why shorts haven't bothered to show much interest in this stock. That being said, Flamel's approach does pose a more serious threat to Xyrem's commercial success and could be on the market as early as 2016 if the drug posts strong data (remember, it's still early stage). As such, I think investors with a long-term outlook should pay special attention to Jazz's plans to further diversify its revenue stream in order to become less dependent on Xyrem moving forward.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

George Budwell owns shares of Jazz Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information